In Brief: Ad, Social Media Claims Scrutinized; Unilever Slims Down; Perrigo Generic Advil Congestion Ready

NAD refers RDK Global advertising to FTC; social media claims trigger FDA warning; Perrigo to launch equivalent of Advil product; Unilever divests Slim-Fast; class-action complaint against Nu Skin; Herbalife makes friends on Capitol Hill; and child-proof liquid nicotine bill introduced.

Claims that RDK Global’s dietary supplement Provailen “stops arthritis pain at the source” and has “zero side effects” could imply the product is an alternative to FDA-approved medication and encourage consumers to forgo treatment, the Council for Responsible Nutrition said in a case it brought to the National Advertising Division. NAD referred the case to the Federal Trade Commission after RDK refused to participate in the review process. The Council of Better Business Bureaus division noted the Coatbridge, Scotland-based firm, which also markets weight-loss supplement brands Phen375, Adiphene, Optimus and KouTea and Brestrogen “breast enhancement cream,” should substantiate a testimonial that suggested the Reishi mushroom formula alleviated a user’s shoulder and joint pain to the point that surgery was not necessary. CRN argued the express and implied benefit claims in the testimonial must reflect typical results when the product is used as directed. The trade group brought the challenge as part of the initiative it supports to expand NAD’s review of supplement claims.

Social media claims on Twitter and Facebook that Zarbee’s Naturals products provide cold and cough relief make the products unapproved...

More from United States

Anti-Vaccine Activists Among New US CDC Vaccine Advisors

 

HHS Secretary Kennedy's new ACIP appointments include multiple members of anti-vaccine groups and people who have spread misinformation about COVID-19 vaccines.

US FDA May Consolidate Support Services After Extensive Cuts

 

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

US FDA’s Rising First-Cycle Complete Response Rate Draws Congress’ Attention

 
• By 

The House Appropriations Committee wants an analysis of how issues that led to CRLs could have been resolved within the first review cycle and seeks an agency crackdown on counterfeit GLP-1 agonists.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

More from North America

ACIP Upheaval Leaves Merck & Co. In A Lurch

 

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By 

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

US FDA Chief Counsel Position Awaits HHS General Counsel Confirmation

 
• By 

Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.